IRLAB Therapeutics (IRLAB) Q2 2026 earnings summary

Executive summary

• Achieved significant progress in clinical development for Parkinson's disease treatments, including advancing multiple first-in-class drug candidates and WHO assigning the generic name linepemat to IRL757.

• Secured international recognition for investigational drugs and strengthened financial position through a successful rights and over-allotment issue, raising SEK 76.5 million before costs.

• Ongoing strategic focus on advancing clinical programs, securing partnerships, and preparing for upcoming milestones.

Financial highlights

• Net sales for Jan–Jun 2026 were SEK 45,764k, up from SEK 23,892k year-over-year, mainly due to a USD 3 million milestone payment from Otsuka.

• Operating loss for Jan–Jun 2026 was SEK -5,975k, a significant improvement from SEK -54,367k in the prior year.

• Cash and cash equivalents at period end were SEK 34,218k, with an additional SEK 76.5m from a share issue booked as a receivable.

• Cash position increased to approximately SEK 102m after net proceeds in Q3 2026.

• Earnings per share improved to SEK -0.12 from SEK -1.28 year-over-year.

Outlook and guidance

• Strategic focus on advancing partnerships and securing at least one commercial agreement within the year.

• LIFT-PD study for linepemat expected to read out by mid-2027.

• Capital raised enables funding of operations beyond the Phase IIb LIFT-PD readout and advancement of IRL1117 toward Phase I.

• Mesdopetam Phase III program to be secured through partnerships or licensing.

• Continued development and preparation for next clinical studies for pirepemat and IRL1117.